NCT05833906 - Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

January 8, 2024

Study Completion Date

January 8, 2024

Conditions

Healthy

Interventions

DRUG

CKR-051 Dose 1

Subjects will be administered 5 g of CKR-051.

DRUG

CKR-051 Dose 2

Subjects will be administered 10 g of CKR-051.

DRUG

CKR-051 Dose 3

Subjects will be administered 10 g of CKR-051.

DRUG

CKR-051 Dose 4

Subjects will be administered 10 g of CKR-051.

DRUG

Placebo

Placebo comparator.

Trial Locations (1)

Seoul National University Hospital, Seoul